Trial Profile
Pilot Phase III immunotherapy study in early breast cancer patients using oxidized mannan-MUC1 [mannan-MUC1 fusion protein]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2006
Price :
$35
*
At a glance
- Drugs Mannan-MUC1-fusion-protein (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms IFCM9
- 07 Nov 2006 New trial record.